Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 2
2(33.3%)
6Total
Phase 1(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04009824Phase 1Completed

Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine

Role: collaborator

NCT02962908Phase 2Completed

A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine

Role: lead

NCT03180801Phase 2Completed

Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model

Role: lead

NCT01226758Phase 1Completed

Influenza Vaccine Challenge Study in Healthy Subjects

Role: lead

NCT01071031Phase 1Completed

HIV Vaccine Study in HIV Positive Patients

Role: lead

NCT01181336Phase 1Completed

Phase 1b Influenza Vaccine Study in Healthy Subjects

Role: lead

All 6 trials loaded